Navigation Links
Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
Date:10/3/2008

ional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the development and commercialization of the T5000 Biosensor System, Ibis' technology, and the revenue potential of certain government contracts and grants. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its most recent quarterly report on Form 10- Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a r
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. SyntheMed Announces New Management Appointments
2. Alba Therapeutics Corporation Announces Promotions
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. 23andMe Announces Breast Cancer Initiative
5. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
6. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
7. Synthetech Announces New Director of Manufacturing
8. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
9. Biotel Announces Record Revenues and Earnings for Fiscal 2008
10. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
11. Helix BioPharma Announces $11.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
...s (CTI),(Nasdaq and MTA: CTIC) announced today tha...hareholders on February 27, 2009 in lieu of the Sp...o take place on February 6, 2009.,Shareholders of ...9, the,record date established by the Board of Dir...eting. Updated proxy materials, including an updat...
... (Nasdaq: NVAX ) a clinical-stage vaccine compan...d Chief Medical Officer, will be presenting at the...nce on January 26, 2009 at the Grand Hyatt in Wash...cus Session ,What benefits are single-use technolo...ns providing in practice, and will be speaking to ...
... with Acute Spinal Cord Injury , Geron Corpora...d and Drug,Administration (FDA) has granted cleara...) application for the clinical trial of GRNOPC1 in...ance enables Geron to move forward with,the world,...l-based therapy,in man. , Geron plans to initi...
Other Biology Technology:Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 3MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy 2
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Research is vital to a cleaner, greener, low carbon future 2By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 1By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 1Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 4Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 5Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 1Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 3
...lts with obstructive sleep apnea benefit significa...e airway pressure (CPAP), a device to improve brea...rted by the National Heart, Lung, and Blood Instit...This is the first study to identify the nightly du...for daytime alertness and functioning. , Research...
...anotubes are nature’s smallest candles. , These ti...y are so small that it takes about 100,000 laid si...r. In the last five years, scientists have discove.... That is, they glow when they are bathed in light... in spots. Others glow all over. , Until now, th...
...alists associated with the Neuroscience Institute ...y Hospital say the ability to incorporate—in real ...g room can improve the functional abilities of pat...st James Leach, MD, and his UC colleagues are amon...onal magnetic resonance imaging (MRI) and “diffusi...
Other Biology News:Longer treatment benefits sleep apnea patients 2Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3Dual-imaging technique useful before -- and during -- brain surgery 2
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer* from Molecular Probes (Invitrogen)
ER-beta Fluorescence polarization Assay Kit from Invitrogen
GIBCO MEM Non-Essential Amino Acids Solution 10 mM (100X), liquid from Invitrogen
...rains are K-12 derivatives that have mutations in ...one reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielde... even though overall expression levels were simila...
Biology Products: